KPTI
Presentaciones 11-21 de junio en la asociación europea de hematología.
Karyopharm Therapeutics Inc. (NASDAQ:
KPTI), an innovation-driven pharmaceutical company, today announced that eight posters relating to XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, and eltanexor, its next generation SINE compound, will be presented at the European Hematology Association (EHA) 2020 Virtual Annual Meeting taking place June 11-21, 2020.
The six selinexor abstracts include: (i) overall survival data from the Phase 2b SADAL study evaluating selinexor in patients with relapsed or refractory diffuse large-B-cell lymphoma (DLBCL) demonstrating a 9-month median overall survival in a patient population in which survival is expected to be <6 months based on several historical controls, with the median overall survival not yet reached in the 29% of patients who had partial or complete responses on single agent selinexor; (ii) a post-hoc analysis from the SADAL study demonstrating clinically meaningful response rates in the subgroup of patients with primary refractory DLBCL and treated with at least two prior regimens; (iii) a post-hoc analysis from the SADAL study demonstrating durable response rates regardless of the number of prior lines of therapy or prior treatment with high dose chemotherapy with autologous stem cell transplant; (iv) an assessment of molecular markers that may predict response to selinexor in patients with DLBCL; (v) data demonstrating the anti-myeloma effects of selinexor in combination with eukaryotic translation initiation factor 4E (eIF4E); and (vi) data demonstrating selinexor’s potential to treat patients with acute myeloid leukemia harboring IDH2 pR172K mutations.
The two eltanexor abstracts include: (i) data demonstrating the efficacy of eltanexor in preclinical models of NPM1-mutated acute myeloid leukemia; and (ii) an assessment of molecular markers that may predict a response to eltanexor in patients with relapsed or refractory multiple myeloma.
“The Phase 2b SADAL study in patients with heavily pretreated DLBCL continues to generate encouraging efficacy and safety data from multiple datasets and post-hoc analyses, including a superior survival benefit over what has historically been observed with other therapies,” said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm. “As we await the decision from the U.S. Food and Drug Administration on our supplemental new drug application expected later this month, our sales force is actively preparing for the potential launch of XPOVIO in the additional indication of relapsed or refractory DLBCL. The SADAL data presented at EHA this year will be an important component of our physician education effort surrounding XPOVIO to treat patients with DLBCL, if approved.”
Details for the EHA 2020 virtual poster presentations are as follows:
Selinexor
Title: Survival Among Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Single Agent Selinexor in the SADAL Study
Lead author: Marie Maerevoet, Institut Jules Bordet
Abstract #: EP1260
Session: 19. Aggressive Non-Hodgkin Lymphoma – Clinical
Title: Efficacy and Safety of Single Agent Oral Selinexor in Patients with Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the SADAL Study
Lead author: Josee Zijlstra, Amsterdam Universitair Medische Centra, Vrije Universiteit, Cancer Center
Abstract #: EP1226
Session: 19. Aggressive Non-Hodgkin lymphoma – Clinical
Title: Effect of Prior Therapy on the Efficacy and Safety Of Oral Selinexor in Patients With Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
Lead author: George Follows, Addenbrooke’s Hospital, Cambridge, United Kingdom
Abstract #: EP1244
Session: 19. Aggressive Non-Hodgkin lymphoma - Clinical
Title: Combined Inhibition of XPO1 and eIF4E Prevents Protein Translation resulting in Synergistic Anti-Myeloma Effects
Lead author: Shirong Li, Columbia University
Abstract #: EP1910
Session: 13. Myeloma and other monoclonal gammopathies – Biology & Translational Research
Title: IDH2 p.R172K Mutations in Patients with Acute Myeloid Leukemia (AML) May Be Associated with Favorable Response to Selinexor Treatment
Lead author: Christopher Walker, Karyopharm Therapeutics Inc.
Abstract #: EP484
Session: 03. Acute myeloid leukemia - Biology & Translational Research
Title: Comprehensive Assessment of Molecular Markers of Selinexor Response in Patients with Diffuse Large B-cell Lymphoma (DLBCL)
Lead author: Christopher Walker, Karyopharm Therapeutics Inc.
Abstract #: EP1328
Session: 20. Lymphoma Biology & Translational Research
Eltanexor
Title: Continuous XPO1 Inhibition with Eltanexor is Highly Effective in NPM1-mutated AML In Vivo
Lead author: Giulia Pianigiani, University of Perugia
Abstract #: EP441
Session: 03. Acute myeloid leukemia - Biology & Translational Research
Title: RNA and DNA Sequencing Reveal Markers of Response to the XPO1 Inhibitor Eltanexor in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Lead author: Christopher Walker, Karyopharm Therapeutics Inc.
Abstract #: EP890
Session: 13. Myeloma and other monoclonal gammopathies - Biology & Translational Research
«Después de nada, o después de todo/ supe que todo no era más que nada.»
